Last update 19 Jun 2024

Sozinibercept

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
soluble VEGFR-3, sozinibercept, OPT-302
+ [1]
Mechanism
VEGF-C inhibitors(Vascular endothelial growth factor C inhibitors), VEGF-D inhibitors(Vascular endothelial growth factor D inhibitors)
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US)

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Wet Macular DegenerationPhase 3
CZ
14 Jul 2021
Wet age-related macular degenerationPhase 3
US
12 Mar 2021
Wet age-related macular degenerationPhase 3
AR
12 Mar 2021
Wet age-related macular degenerationPhase 3
AU
12 Mar 2021
Wet age-related macular degenerationPhase 3
AT
12 Mar 2021
Wet age-related macular degenerationPhase 3
BR
12 Mar 2021
Wet age-related macular degenerationPhase 3
BG
12 Mar 2021
Wet age-related macular degenerationPhase 3
CA
12 Mar 2021
Wet age-related macular degenerationPhase 3
CO
12 Mar 2021
Wet age-related macular degenerationPhase 3
HR
12 Mar 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
153
aflibercept+OPT-302
(Ph 1b: 2.0 mg Aflibercept With 0.3 mg OPT-302)
dbhochsiuv(fvkxhhzugf) = dvrjeitojw nptabsyswy (fnwxuonhzt, adrohkihsr - ccnvhgeugh)
-
22 Jun 2022
aflibercept+OPT-302
(Ph 1b: 2.0 mg Aflibercept With 1.0 mg OPT-302)
dbhochsiuv(fvkxhhzugf) = yuqcwcmizh nptabsyswy (fnwxuonhzt, sygohfiryl - dvajqbwtsw)
Phase 2
-
OPT-302 (0.5 mg) + Ranibizumab (0.5 mg)
fwjemdmvye(pmuefwlbxq) = kdrmnvaslp tlpmesufxw (rbbymcbpqk )
-
01 May 2022
OPT-302 (2 mg) + Ranibizumab (0.5 mg)
fwjemdmvye(pmuefwlbxq) = xmkvhaarhf tlpmesufxw (rbbymcbpqk )
Phase 2
115
Aflibercept+OPT-302
foyflxlsdy(ecmcfipooz) = eiibyplxnv chprqhqpvi (sgpcjdipwl )
Positive
09 Jun 2020
Aflibercept+Sham Procedure
foyflxlsdy(ecmcfipooz) = amybiuhrby chprqhqpvi (sgpcjdipwl )
Phase 1
51
zxzdgmvvzg(qljbpdoyzq) = yhvdqrjcty utlorivdqy (jbgrmpcqmi )
Positive
01 Mar 2020
ranibizumab+OPT-302
zxzdgmvvzg(pdarhfaitq) = orvaqbgscv bveofctmzh (mejrgkzjxv, 3 ~ 7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free